Related Experiment Videos
[Inhibitory effect of IGF-II antisense RNA on malignant phenotype of hepatocellular carcinoma]
1Department of Gastroenterology, Zhujiang Hospital, First Military Medical University, Guangzhou.
Objective:
Inhibitory effect of insulin like growth factor II (IGF-II) antisense RNA on malignant phenotype of hepatic cancer cells was studied.
Methods:
A 0.1 kb cDNA of human IGF-II was reversely inserted into a eukaryotic expression vector of pcDNA3 and an IGF-II antisense RNA expression vector of pIGF-II As was obtained. The pIGF-II As was then introduced into human hepatic cancer cell line SMMC-7721. The effect of IGF-II antisense RNA which was expressed by pIGF-II As on SMMC-7721 cell cycles progression was measured with FCM.
Results:
The coloning formation in anchorage-independent assay of SMMC-7721 cells with pIGF-II As was significantly decreased by comparison with control groups of SMMC-7721 cells and SMMC-7721 cells transfected with pcDNA3 vector alone. FCM analysis showed that the S phase of cell cycles for SMMC-7721 cells with pIGF-II As was increased, but there were no obvious changes in the control groups of SMMC-7721 cells and SMMC-7721 cells with pcDNA3.
Conclusion:
The pIGF-II As of IGF-II antisense RNA acts as an inhibitor on carcinogenesis of the SMMC-7721 cells in vitro.
Insights
Insulin-like growth factor II (IGF-II) antisense RNA effectively inhibited the malignant characteristics of hepatic cancer cells. This novel approach shows promise in controlling liver cancer progression in vitro.
Area of Science:
- Molecular Biology
- Cancer Research
- Hepatology
Context:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Understanding the molecular mechanisms driving HCC proliferation is crucial for developing targeted therapies.
- Insulin-like Growth Factor II (IGF-II) is implicated in the development and progression of various cancers, including HCC.
Purpose:
- To investigate the inhibitory effect of IGF-II antisense RNA on the malignant phenotype of human hepatic cancer cells (SMMC-7721).
- To construct and validate an IGF-II antisense RNA expression vector (pIGF-II As).
- To assess the impact of IGF-II antisense RNA expression on SMMC-7721 cell cycle progression.
Summary:
- A human IGF-II cDNA was used to create the pIGF-II As vector, which was then introduced into SMMC-7721 cells.
- Anchorage-independent colony formation of SMMC-7721 cells transfected with pIGF-II As was significantly reduced compared to control groups.
- Flow cytometry analysis revealed an increase in the S phase of the cell cycle in cells expressing IGF-II antisense RNA, suggesting cell cycle arrest.
Impact:
- IGF-II antisense RNA demonstrates potent inhibitory effects on the carcinogenesis of SMMC-7721 cells in vitro.
- This study provides a potential therapeutic strategy targeting IGF-II for liver cancer treatment.
- The findings contribute to the development of RNA-based therapies for hepatocellular carcinoma.